Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S293-S297

  Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cirrhosis; Drug resistance; Hepatocellular carcinoma; Interferon ; Nucleos(t)ide analogs; Pegylated interferon

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; PEGINTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; NUCLEOSIDE; NUCLEOTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; CHEMOPROPHYLAXIS; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; PATHOPHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; NUCLEOSIDES; NUCLEOTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 77953725375     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60519-1     Document Type: Article

References (43)

1. Liaw YF, Chu CM Hepatitis B Vims Infection. Lancet 2009, 373:582-592.
2. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46:395-401.
3. Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009, 49:1859-1867.
4. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
5. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45-52.
6. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
7. Chen YC, Chu CM, Liaw YF Age-specific prognosis following spontaneous HBeAg seroconversion in chronic hepatitis B. Hepatology 2010, 51:435-444.
8. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005, 77:173-179.
9. Fattovich G, Bortolotti F, Donato F Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-352.
10. Chu CM, Liaw YF Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010, 15:133-143.
11. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
12. Chu CM, Liaw YF Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006, 26:142-152.
13. Chen YC, Chu CM, Yeh CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007, 1:267-273.
14. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
15. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Nati Cancer Inst 2008, 100:1134-1143.
16. Liaw YF Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006, 11:669-679.
17. Kao JH Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007, 1:415-430.
18. Poustchi H, Mohamadkhani A, Bowden S, et al. Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. J Viral Hepat 2008, 15:753-760.
19. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific Consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008, 2:263-283.
20. Liaw YF Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009, 29(Sl):100-107.
21. Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003, 37:1309-1319.
22. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-1427.
23. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004, 39:804-810.
24. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139-145.
25. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37:756-763.
26. Papatheodoridis GV, Petraki K, Cholongitas E, et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2005, 12:199-206.
27. Brunetto MR, Oliveri F, Coco B, et al. The outcome of chronic anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263-270.
28. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998, 93:896-900.
29. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-1077.
30. Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009, 16:265-271.
31. Camma C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593-602.
32. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695. for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
33. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217. for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.
34. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
35. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
36. Liaw YF, Chang TT, Wu SS, et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologie improvement in patients with HBeAg(+) and (-) chronic hepatitis B: Results from studies ETV-022, -027 and -901. Hepatology 2008, 48(Suppl):706A. Abstract 894.
37. Yuen MF, Seto WK, Chow DHF, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007, 12:1295-1303.
38. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531. on behalf of the CALM Study Group.
39. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004, 40:883-891. for the Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy.
40. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005, 32:173-184. for the the Inuyama Hepatitis Study Group.
41. Chien RN, Liaw YF Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008, 22:1081-1092.
42. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005, 42:121-129.
43. Liaw YF Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005, 25(Suppl l):40-47.